Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

Nisha Unni; Carlos L. Arteaga

doi:10.1001/jamaoncol.2019.2525

Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1564-1565
Number of pages	2
Journal	JAMA Oncology
Volume	5
Issue number	11
DOIs	https://doi.org/10.1001/jamaoncol.2019.2525
State	Published - Nov 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.2525

Cite this

@article{12d857aeebc54bffb5317182faef8f99,

title = "Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?",

author = "Nisha Unni and Arteaga, {Carlos L.}",

note = "Funding Information: serving on the advisory board and speaker bureau fr Eisai Inc. Dr Arteaga reported receiving grant support from Lilly, Pfizer, Radius, PUMA Biotechnology, Bayer, and Takeda; serving in advisory roles with Novartis, AbbVie, Lilly, Sanofi, Radius, TAIHO Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, and Athenex; holding stock options in Provista and Y-TRAP; and serving as a member of the scientific advisory board of the Susan G. Komen Foundation. No other disclosures were reported.",

year = "2019",

month = nov,

doi = "10.1001/jamaoncol.2019.2525",

language = "English (US)",

volume = "5",

pages = "1564--1565",

journal = "JAMA Oncology",

issn = "2374-2437",